Hybio Pharmaceutical's 2025 First Quarter Performance Forecast
Hybio Pharmaceutical's 2025 First Quarter Performance Forecast: Revenue and Profit Achieve Double-Digit Growth, GLP-1's International Expansion Is Just the Beginning, and a Formulation Matrix is "Fired on All Cylinders."
On March 26th, Hybio Pharmaceutical (300199) released its performance forecast for the first quarter of 2025, with both revenue and profit achieving significant growth: the revenue in the first quarter of 2025 is expected to reach 290-310 million RMB, a year-on-year increase of 93.00% to 106.31%, hitting a new historical high in performance growth rate; the net profit attributable to shareholders of the listed company is expected to be 60-72 million RMB, an increase of 74.1-86.1 million RMB compared to the same period last year, marking a turnaround from loss to profit.
Hybio Pharmaceutical's business covers four major segments: peptide preparations, peptide APIs, small nucleic acids, and innovative drug CDMO. The overseas expansion of GLP-1 preparations has entered a harvest period. In the future, peptide formulation matrix will provide sustainable momentum for the company's performance growth, highlighting its stable long-term value.
Starting from 2025, Hybio Pharmaceutical will enter a period of explosive growth in the overseas expansion of its formulations. Over the next decade, nearly 20 peptide and small nucleic acid drug formulations targeting the international market are expected to be successively approved for marketing, covering multiple therapeutic areas such as weight loss, diabetes, rare diseases, osteoporosis, and hyperlipidemia. According to the public financial report data for the first three quarters of 2024, the international business of Hybio Pharmaceutical accounted for nearly 50% of its total business, and this figure is expected to increase significantly in 2025. The internationalization process of these formulations will enable the continuous optimization of Hybio Pharmaceutical's revenue and profit structure, as well as high-quality growth of its main business.
In terms of the formulation business, Hybio Pharmaceutical's overseas strategy is not limited to the output of a single product. Instead, it takes GLP-1 as a starting point to build an international high-end formulation product system. In the GLP-1 track, the company adopts a "multi-generational product parallel" strategy: on the one hand, it promotes the marketization process of liraglutide first generic drug in the United States; on the other hand, it proactively advances the in-depth development and commercial layout of products such as semaglutide and tirzepatide. At present, both the weight management and anti-diabetic indications of the company's Semaglutide Injection have entered Phase III clinical trials. In addition, the company has also laid out blockbuster products such as glatiramer, retatrutide, and inclisiran, achieving a gradient formulation product layout in the international market.
On December 23, 2024, the company's Liraglutide Injection received the first generic drug approval from the U.S. FDA for marketing. For generic drug development, Liraglutide poses significant challenges to enterprises in terms of process development, impurity levels, and stability in large-scale production. This approval also demonstrates that the company has achieved a high level of R&D technology reserve and large-scale stable production capabilities in the international peptide preparation field.
As of 2025, the company has over 50 domestic and overseas preparation product pipelines covering different R&D stages, gradually forming a healthy and sustainable development rhythm of "researching a batch, applying for a batch, and launching a batch". This diversified layout not only ensures the current efficiency of commercialization but also lays a technical foundation for continuously deepening the international market.
The phased achievements in the GLP-1 track are only the starting point of the company's international journey. In the future, the company will continue to focus on the R&D fields of peptide and small nucleic acid drugs, and actively explore in areas such as AI empowering the company's core businesses, drug development, cloud computing support, data governance, and talent cultivation, aiming to further accelerate new drug R&D and pharmaceutical intelligence, and build an innovation-driven new pharmaceutical ecosystem.
About Hybio Pharmaceutical
Hybio Pharmaceutical, founded in 2003, has always been dedicated to the fields of Peptide Drugs and small nucleic acids. Its products and businesses cover innovative peptide drugs, high-barrier peptide generic drugs, peptide and small nucleic acid APIs, and CDMO services. Up to now, it has established a vertically integrated industrial chain spanning upstream, midstream and downstream, ensuring full-chain control from raw materials to pharmaceuticals. Hybio Pharmaceutical has always adhered to the vision of "sustained innovation to become a leader in the peptide industry" and the eternal mission of "safeguarding life and health". Meanwhile, the company actively seeks in-depth cooperation with domestic and foreign pharmaceutical enterprises, including joint development, technology introduction, transfer of mature varieties, cooperative marketing, and CDMO services, aiming to achieve resource sharing, complementary advantages and joint creation of a better future.